Subscribe
shutterstock_1425740486_ii_studio
II Studio / Shutterstock.com
7 November 2019AmericasRory O'Neill

US government sues Gilead for patent infringement over HIV drugs

The US government is suing Gilead for patent infringement, claiming that the pharmaceutical company has been piggybacking on public research to earn billions from its HIV drugs.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Sanders calls on USPTO to block Gilead patent extension
9 December 2019   US presidential candidate Bernie Sanders has called on the US Patent and Trademark Office to block extensions to two Gilead Sciences patents covering HIV prevention drugs including Descovy.
Americas
US govt PrEP patents are invalid, Gilead tells court
27 January 2020   Gilead Sciences has accused a US government agency of withholding information from the US Patent and Trademark Office when filing two patents for HIV pre-exposure prophylaxis.
Americas
Gilead suffers defeat at PTAB in government PrEP battle
6 February 2020   Gilead has suffered a blow in its efforts to invalidate the US government’s patent rights for PrEP, as the Patent Trial and Appeal Board threw out two of its four patent challenges.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Sanders calls on USPTO to block Gilead patent extension
9 December 2019   US presidential candidate Bernie Sanders has called on the US Patent and Trademark Office to block extensions to two Gilead Sciences patents covering HIV prevention drugs including Descovy.
Americas
US govt PrEP patents are invalid, Gilead tells court
27 January 2020   Gilead Sciences has accused a US government agency of withholding information from the US Patent and Trademark Office when filing two patents for HIV pre-exposure prophylaxis.
Americas
Gilead suffers defeat at PTAB in government PrEP battle
6 February 2020   Gilead has suffered a blow in its efforts to invalidate the US government’s patent rights for PrEP, as the Patent Trial and Appeal Board threw out two of its four patent challenges.

More on this story

Americas
Sanders calls on USPTO to block Gilead patent extension
9 December 2019   US presidential candidate Bernie Sanders has called on the US Patent and Trademark Office to block extensions to two Gilead Sciences patents covering HIV prevention drugs including Descovy.
Americas
US govt PrEP patents are invalid, Gilead tells court
27 January 2020   Gilead Sciences has accused a US government agency of withholding information from the US Patent and Trademark Office when filing two patents for HIV pre-exposure prophylaxis.
Americas
Gilead suffers defeat at PTAB in government PrEP battle
6 February 2020   Gilead has suffered a blow in its efforts to invalidate the US government’s patent rights for PrEP, as the Patent Trial and Appeal Board threw out two of its four patent challenges.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York